0001179110-20-007676.txt : 20200622 0001179110-20-007676.hdr.sgml : 20200622 20200622162156 ACCESSION NUMBER: 0001179110-20-007676 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200618 FILED AS OF DATE: 20200622 DATE AS OF CHANGE: 20200622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Durso-Bumpus Debra CENTRAL INDEX KEY: 0001802970 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 20979088 MAIL ADDRESS: STREET 1: C/O BLUEPRINT MEDICINES CORORATION STREET 2: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-06-18 0 0001597264 Blueprint Medicines Corp BPMC 0001802970 Durso-Bumpus Debra C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief People Officer Common Stock 2020-06-18 4 M 0 2500 18 A 22005 D Common Stock 2020-06-18 4 S 0 2500 75.18 D 19505 D Stock Option (Right to Buy) 18 2020-06-18 4 M 0 2500 0 D 2025-04-27 Common Stock 2500 8966 D Effected pursuant to a trading plan adopted on May 15, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. This option is fully vested as of the date hereof. /s/ Christopher Frankenfield, Attorney-in-Fact 2020-06-22